Astrana Health, Inc.

Astrana Health, Inc. operates as a physician-centric, technology-powered, risk-bearing healthcare company within the U.S. healthcare industry, which is undergoing a significant transformation toward value-based and results-oriented models. The filing cites CMS estimates that total U.S. healthcare expenditures are expected to grow at an average annual rate of 5.8% from 2024 to 2033, reaching $8.6 trillion by 2033, with health spending projected to grow 1.5% faster than GDP per year on average over 2024–2033, and the healthcare share of GDP expected to grow from 17.6% in 2023 to 20.3% in 2033. Medicare spending increased by 7.8% to $1.1 trillion, and Medicaid spending increased by 6.6% to $931.7 billion in 2024, accounting for 21% and 18% of total health expenditures, respectively, while private health insurance spending increased by 8.8% to $1.6 trillion in 2024, accounting for 31% of total health expenditures. The company positions itself to capitalize on the shift toward value-based care, leveraging its integrated healthcare delivery platform that enables providers to participate in value-based care arrangements.

The filing identifies several primary competitors across its business lines. For its IPAs, competitors include Regal Medical Group and Lakeside Medical Group, which are part of Heritage Provider Network, as well as Optum, a subsidiary of UnitedHealth Group. For its ACOs, major competitors include Privia Health and Aledade. For its outpatient clinics, competitors include RadNet and Envision Healthcare, as well as Optum with its own urgent care centers, clinics, and diagnostic centers. For its hospital, competitors include Hoag Health Center and University of California-Irvine Health. For its MSOs, competitors include Conifer Health Solutions, InnovAccer, Arcadia, Lightbeam Health Solutions, and Lumeris. The company states its key strength lies in its combined clinical, administrative, and technology capabilities, noting that very few organizations provide all three types of services to approximately 1.6 million patients as of December 31, 2025 ¹.

Astrana generates revenue through five primary streams: capitation revenue, risk pool settlements and incentives, management fee income, fee-for-service revenue, and other revenue. Capitation revenue consists primarily of capitated fees for medical services under arrangements with managed care providers, including HMOs, and includes global capitation arrangements through its Restricted Knox-Keene licensed health plans. Risk pool settlements and incentives include hospital shared-risk and health plan shared-risk arrangements, as well as incentives under pay-for-performance programs. Management fee income encompasses fees for management, provider access, physician advisory, healthcare staffing, enrollment outreach, administrative, and other non-medical services provided to IPAs, ACOs, hospitals, health plans, and other healthcare providers. Fee-for-service revenue represents revenue earned under contracts where the company bills and collects the professional component of charges for medical services rendered by its affiliated hospital, contracted physicians, and employed physicians. Other revenue primarily encompasses revenue earned from maternity care and the Hospital Quality Assurance Fee Program. The company's revenue is diversified among its operations, and multi-year renewable contractual arrangements are typical.

The company operates through three reportable segments: Care Partners, Care Delivery, and Care Enablement. The Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in provider partners. It consists of a network of risk-bearing organizations that encompass independent practice associations, accountable care organizations, and state-specific entities such as Restricted Knox-Keene licensed health plans in California. As of December 31, 2025, the company managed a total of 28 independent risk-bearing organizations ². The Care Partners segment generated segment revenue of $3,022,602 thousand ³ and segment operating income of $154,967 thousand ⁴ for the year ended December 31, 2025. The Care Delivery segment is a patient-centric, data-driven organization focused on delivering high-quality and accessible care, serving approximately 1.6 million patients annually ⁵ and spanning over 60 locations ⁶, including primary care clinics, specialty care clinics, ancillary service providers, and an acute care hospital facility. The Care Delivery segment generated segment revenue of $250,742 thousand ⁷ and segment operating loss of $2,015 thousand ⁸ for the year ended December 31, 2025. The Care Enablement segment represents a comprehensive platform that integrates clinical, operational, financial, and administrative information, powered by proprietary technology, and provides solutions to payers and providers, including independent physicians, providers, medical groups, and ACOs. The Care Enablement segment generated segment revenue of $246,660 thousand ⁹ and segment operating income of $39,716 thousand ¹⁰ for the year ended December 31, 2025.

The company's physician network consists of more than 20,000 contracted physicians ¹¹, and as of December 31, 2025, it was responsible for coordinating value-based care for approximately 1.6 million patients ¹². The company's revenue streams are diversified among its various operations. Capitation revenue for the year ended December 31, 2025 was $2,924,265 thousand ¹³, risk pool settlements and incentives were $86,199 thousand ¹⁴, management fee income was $30,394 thousand ¹⁵, fee-for-service revenue was $112,635 thousand ¹⁶, and other revenue was $28,276 thousand ¹⁷. Total revenue for the year ended December 31, 2025 was $3,181,769 thousand ¹⁸. The company's cost of services, excluding depreciation and amortization, was $2,840,239 thousand ¹⁹, general and administrative expenses were $217,256 thousand ²⁰, and depreciation and amortization was $45,749 thousand ²¹ for the year ended December 31, 2025.

On July 1, 2025, the company completed the acquisition of certain businesses and assets of Prospect Medical Holdings, Inc. for a purchase price of $674.9 million ²². Prospect is a physician-centric risk-bearing healthcare company that operates an integrated healthcare delivery platform enabling a network of over 11,000 providers ²³ to participate in value-based care arrangements. The acquisition significantly expanded the company's provider network and enhanced its ability to offer increased access, quality, and value to its members. On February 26, 2025, the company entered into the Second Amended and Restated Credit Agreement with Truist Bank, which provides for a five-year revolving credit facility of $300.0 million ²⁴, a five-year term loan A credit facility of $250.0 million ²⁵, and a five-year delayed draw term loan credit facility of up to $745.0 million ²⁶, of which $707.3 million ²⁷ was drawn down to fund the Prospect Acquisition. During the three months ended December 31, 2025, 633,844 shares ²⁸ were repurchased under the company's share repurchase plan, and as of December 31, 2025, $35.9 million ²⁹ remained available under the repurchase plan. The company also partnered with a provider group in Southern California and with Intermountain Health across southern Nevada with the collaboration goal to expand access to coordinated, high-quality care.

Total revenue for the year ended December 31, 2025 was $3,181,769 thousand ³⁰, compared to $2,034,540 thousand ³¹ for the year ended December 31, 2024, an increase of $1,147,229 thousand or 56% ³². The increase was partially attributable to the acquisition of Prospect, which contributed approximately $616.3 million ³³ of revenue from the acquisition date. Net income attributable to Astrana Health, Inc. for the year ended December 31, 2025 was $22,487 thousand ³⁴, compared to $43,149 thousand ³⁵ for the year ended December 31, 2024, a decrease of $20,662 thousand or 48% ³⁶. Adjusted EBITDA for the year ended December 31, 2025 was $205,424 thousand ³⁷, compared to $170,370 thousand ³⁸ for the year ended December 31, 2024, an increase of $35,054 thousand or 21% ³⁹. Net cash provided by operating activities for the year ended December 31, 2025 was $114,597 thousand ⁴⁰, compared to $52,198 thousand ⁴¹ for the year ended December 31, 2024.

The company's primary growth vector is the expansion of its provider network and capabilities through strategic acquisitions, most notably the Prospect Acquisition completed on July 1, 2025 for a purchase price of $674.9 million ⁴². Prospect enables a network of over 11,000 providers ⁴³ to participate in value-based care arrangements across Medicare Advantage, Medicaid, and Commercial lines of business, and operates a California Restricted Knox-Keene-licensed health plan, an MSO, a specialty pharmacy, and a fully-accredited acute care hospital. The acquisition significantly expanded the company's provider network and enhanced its ability to offer increased access, quality, and value to its members. The company also formed partnerships with a provider group in Southern California and with Intermountain Health across southern Nevada with the collaboration goal to expand access to coordinated, high-quality care, enhance primary care access, improve patient outcomes, and advance the healthcare infrastructure through shared technology and care management programs.

The company's growth strategy also involves building a network of medical groups and integrated physician networks through organic growth and acquisitions or alliances with other medical service providers. The company states it seeks and actively pursues growth opportunities, both organically and through acquisitions or alliances with other medical service providers. As part of its growth strategy, the company regularly reviews potential strategic opportunities, including acquisitions, partnerships, investments, and divestitures. The company's Care Enablement segment provides solutions to payers and providers, including independent physicians, providers, and medical groups, as well as ACOs, and the company's platform meets providers and payers wherever they are on the spectrum of total cost of care, offering solutions for FFS entities and to providers open to taking upside and downside risks on professional and institutional spending, and across all patient types, including Medicare, Medicaid, Commercial, and Exchange-insured patients.

The filing discusses the margin trajectory and cost structure evolution primarily through the lens of segment operating income. For the year ended December 31, 2025, the Care Partners segment generated operating income of $154,967 thousand ⁴⁴, the Care Delivery segment generated an operating loss of $2,015 thousand ⁴⁵, and the Care Enablement segment generated operating income of $39,716 thousand ⁴⁶. The company's cost of services, excluding depreciation and amortization, was $2,840,239 thousand ⁴⁷ for the year ended December 31, 2025, representing 89.3% of total revenue. General and administrative expenses were $217,256 thousand ⁴⁸ for the year ended December 31, 2025. The company's Adjusted EBITDA margin was 6% ⁴⁹ for the year ended December 31, 2025, compared to 8% ⁵⁰ for the year ended December 31, 2024. The company expects the OBBBA will not have a material impact on tax expense and did not identify a material impact in 2025.

The company's operational outlook is focused on integrating the Prospect acquisition and managing its expanded provider network. As of December 31, 2025, the company and its consolidated VIEs had approximately 3,000 employees ⁵¹. The company's physician network consisted of over 20,000 contracted physicians ⁵² as of December 31, 2025. The company's Care Delivery organization spans over 60 locations ⁵³. The company's technology infrastructure is a key component of its operations, with its Care Enablement segment representing a comprehensive platform that integrates clinical, operational, financial, and administrative information, all powered by its proprietary technology suite. The company's cybersecurity program is aligned with the National Institute of Standards and Technology Cybersecurity Framework, and the company utilizes a cross-functional governance structure that engages enterprise risk management, compliance, IT, legal, privacy, and data governance teams.

The company's capital allocation strategy includes share repurchases and debt management. In December 2022, the Board of Directors approved a share repurchase program authorizing the company to repurchase up to $50.0 million ⁵⁴ of its shares of common stock. In February 2026, the Board of Directors increased the total authorization under the share repurchase program to $100.0 million ⁵⁵ of its shares of common stock, including the $35.9 million ⁵⁶ that remained available under the previously announced stock repurchase program. During the three months ended December 31, 2025, 633,844 shares ⁵⁷ were repurchased under the company's share repurchase plan. The company's capital expenditures for purchases of property and equipment were $10,106 thousand ⁵⁸ for the year ended December 31, 2025. The company does not anticipate paying cash dividends on its common stock in the foreseeable future. The company's debt balance as of December 31, 2025 consisted of $930,243 thousand ⁵⁹ in Term Loans and $122,000 thousand ⁶⁰ in Revolver Loan, totaling $1,052,243 thousand ⁶¹.

The filing identifies several headwinds and constraints. The company faces risks related to the Prospect Acquisition, including a material increase in its indebtedness, challenges in integrating Prospect into its operations, and risks related to the acquired hospital. The company's ability to raise additional capital to grow may be limited. The company could be negatively impacted by uncertain or adverse economic conditions and/or public health crises. Potential changes in laws, accounting principles, and regulations related to VIEs could impact the company's consolidation of total revenues derived from its affiliated physician groups. The company currently derives a substantial portion of its revenues in California and is vulnerable to changes in that state. The company's business strategy involves acquisitions and strategic partnerships, which can be costly, risky, and complex. The company's complex legal structure may cause tax authorities to question its tax filing status. The company could experience significant losses under capitation contracts if its expenses exceed revenues. The company's revenues and operations are dependent on a limited number of key payers, with four payers accounting for an aggregate of 59.8% ⁶² of total net revenue for the year ended December 31, 2025.

The filing also identifies regulatory and macro factors as constraints. The healthcare industry is intensely regulated at the federal, state, and local levels, and government authorities may determine that the company fails to comply with applicable laws or regulations. Changes to federal, state, and local healthcare law, including the ACA and/or the adoption of a primarily publicly funded healthcare system, may negatively impact the company's business. Medicaid, Medicare, or Marketplace capitation rates may be insufficient to fully cover the company's medical care costs. Federal or state legislative or regulatory changes could negatively impact the company, including changes to the Medicaid program created by the One Big Beautiful Bill Act. The success of the company's participation in the ACO REACH Model or any CMS or CMMI sponsored model is not guaranteed due to political risks, uncertainties of administration, program economics, and the requirement of the company to maintain significant capital reserves. Laws regulating the corporate practice of medicine could restrict the manner in which the company is permitted to conduct its business.

The company faces material risks from its increased indebtedness following the Prospect Acquisition, with the Second Amended and Restated Credit Agreement providing for a delayed draw term loan of up to $745.0 million ⁶³, of which $707.3 million ⁶⁴ was drawn down, and total debt as of December 31, 2025 was $1,052,243 thousand ⁶⁵. The company's revenues are highly concentrated, with four payers accounting for 59.8% ⁶⁶ of total net revenue for the year ended December 31, 2025, and termination of contracts with these key payers would materially adversely affect results. The company could experience significant losses under capitation contracts if care-related expenses exceed projected levels, as capitation payments represent a prospective budget and deficits are not capped. The company's operations are heavily dependent on California, where it currently primarily operates, and any material changes in that state's healthcare delivery environment could have an adverse effect. The company identified a material weakness in internal control over financial reporting related to accounting for business combinations and the risks posed by changes in the business caused by growth and increased complexity, which could result in material misstatements in financial statements if not remediated.

Management's message emphasizes the company's position as a leading physician-centric, technology-powered, risk-bearing healthcare company and highlights the significant milestone of the Prospect Acquisition completed on July 1, 2025 for a purchase price of $674.9 million ⁶⁷. The filing states that management believes the company is well-positioned to capitalize on the shift in the U.S. healthcare industry toward value-based and results-oriented healthcare, with a focus on patient satisfaction, high-quality care, and cost efficiency. Management's strategic priorities for the period ahead include integrating the Prospect acquisition to significantly expand the provider network and enhance the ability to offer increased access, quality, and value to members; navigating the policy changes introduced by the One Big Beautiful Bill Act, which management views as manageable headwinds; and continuing to build a network of medical groups and integrated physician networks through organic growth and strategic acquisitions.